Phaseline

Targets › BLEOMYCIN

BLEOMYCIN: drug programs, companies and trials

1 program from 1 company in 2 trials: 2 Phase 3; Oncology.

Open in Phaseline: the race on BLEOMYCIN, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
European Organisation for Research and Treatment of Cancer - EORTCbleomycin sulfate
DNA/RNA crosslinking and degradation
BLEOMYCINPhase 3Lymphoma–

Conditions

Lymphoma (2)

Modalities

mixed (1)

Companies

European Organisation for Research and Treatment of Cancer - EORTC (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.